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ABSTRACT
Biologics are complex proteins derived from living organisms that have been used successfully in treating many 
different diseases. As some biologics approach patent expiration, the development of drugs that are similar to the 
approved biological agents, known as biosimilars, has gained significant interest, primarily as a more affordable 
option for patients. Because of the structural complexity of large proteins and the inherent heterogeneity 
associated with culturing and manufacturing conditions, biosimilars are highly similar, but not identical to the 
approved ‘reference’ agents. Any subtle changes in the manufacturing processes may result in altered function 
and immunogenicity of the biosimilars, potentially affecting their efficacy and safety profile. Thus, stringent 
regulatory framework and requirements are necessary to ensure biosimilars are comparable in quality, efficacy, 
and safety with the reference agents and suitable for clinical use. As this field continues to evolve and more 
biosimilars are expected to become available in the near future, physicians will need to make informed decisions 
in the clinical use of biosimilars to ensure that high-quality, safe, and affordable drugs are accessible to patients. 
This article summarises current considerations, regulatory processes, and challenges in this rapidly evolving field.
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中文摘要
關於生物製劑的醫生需知
張文勇
生物製劑是來源自活生物的蛋白複合物，已被成功用於治療多種不同疾病。由於部分生物製劑的專
利即將期滿，一些與獲批生物製劑相似、稱為生物仿製藥的藥物發展備受關注，成為對病人而言更
能負擔的選擇。因為大蛋白質的結構複雜，加上與培植及生產環境相關的變數，所以雖然生物仿製
藥與獲認可的「參考」藥物高度相似，但並非完全相同。在製造過程中任何細微的變化，都可能改
變生物仿製藥的功能及免疫原性，而可能影響其療效和安全性。因此，必須要有嚴格的監管框架及
要求，以確保生物仿製藥與參考藥物在品質、療效及安全性相若，並適合臨床使用。隨着這領域的
不斷發展，在不久將來會有更多生物仿製藥面世，醫生將需要在使用生物仿製藥上作出明智的決
策，以確保患者可獲得高品質、安全而且負擔得起的藥物。本文總結了在這個正在迅速演變的領域
中現今的顧慮、監管程序和挑戰。
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INTRODUCTION
Biologics, also known as ‘biological medicinal 
products’ or ‘biological medicines’, are drugs that are 
derived from living organisms by means of recombinant 
DNA and / or controlled gene-expression methods. 
Unlike small-molecule drugs, they cannot be easily 
synthesised from chemical processes. Biologics have 
been in use in medicine for a long time and the common 
biologics include vaccines, insulins, hormones, blood 
products and factors, and antibodies. 
Monoclonal antibodies are an important breakthrough 
in biologic therapies that have become the cornerstone 
of treatment for cancer and a range of immunological 
illnesses. Rituximab, a chimeric IgG1, anti-CD20 
monoclonal antibody, is a good example of a 
monoclonal antibody that has revolutionised the 
treatment of a number of diseases, including non-
Hodgkin lymphoma, chronic lymphocytic leukaemia, 
rheumatoid arthritis, and polyangiitis. Although 
associated with improved patient outcomes, the high 
costs of monoclonal antibodies and other biologics 
raise concerns about the financial burden to patients and 
health care payers. The cost of rituximab for rheumatoid 
arthritis can amount to more than HK$110,000 per 
patient per year (Table 1). The high costs may be a 
prohibitive barrier to some patients and may lead to 
restricted access in many health care systems around the 
world due to budget constraints. 
Since many biologics, including monoclonal antibodies, 
are approaching their patent-expiration dates, 
pharmaceutical companies are now developing similar 
versions of these agents. The advantages of biosimilars 
over the original biologics include the potential for cost 
saving and, thus, improving patient access to treatment. 
However, the replication of complex, intricate proteins 
with tertiary and quaternary structures is inherently 
difficult, and any subtle changes in the manufacturing 
processes may result in altered function, efficacy, and 
safety profile. In order to gain marketing approval, 
biosimilars must meet strict regulatory criteria and 
demonstrate comparability in quality, efficacy, and 
safety with the original biologics. As more biosimilars 
are expected to become available in the near future, 
physicians will need to make informed decisions in 
clinical practice when using biosimilars in place of 
the original biologics. This article summarises current 
considerations, regulatory processes, and challenges in 
this rapidly evolving field. 
BIOSIMILARS
A biosimilar, also known as a follow-on biologic or 
subsequent-entry biologic, is defined by the European 
Medicines Agency (EMA) as a “version of an 
already authorized biological medicinal product with 
demonstrated similarity in quality characteristics, 
biological activity, efficacy and safety, based on a 
comprehensive comparability exercise”.1 Similarly, the 
US Food and Drug Administration (FDA) requires a 
biosimilar to be “highly similar to the reference product 
notwithstanding minor differences in clinically inactive 
components” and for which there are “no clinically 
meaningful differences between the biological product 
and the reference product in terms of safety, purity and 
potency”.2 These strict definitions must be fulfilled by 
a medicine to be considered as a biosimilar by the two 
regulatory authorities. 
BIOSIMILARS VERSUS REFERENCE 
PRODUCTS: HOW SIMILAR ARE 
THEY? 
There are substantial challenges associated with the 
synthesis of a ‘highly similar’ copy of the original 
biologic. Unlike small-molecule drugs, which are 
small in size, stable, and have well-defined chemical 
structures, biologics such as monoclonal antibodies are 
large and highly complex, with molecular weights up 
to 150 kDa. Their complexity is not only influenced 
by the amino acid sequence, but also by the secondary, 
tertiary and quaternary structures, or, in other words, 
the way proteins are folded and cross-linked to form 
three-dimensional structures. Biologics are unstable 
and the protein structures are often altered by post-
translational modifications such as glycosylation, 
phosphorylation, methylation and deamidation, which 
may result in intrinsic molecular heterogeneity and 
affect the biological activity. The heterogeneity is 
further increased by conditions of cellular synthesis, 
such as the cell type used to produce the protein, culture 
conditions, purification methods, stabilisation, storage, 
and packaging conditions. All biologic agents are also 
potentially immunogenic; subtle structural differences 
or alternations in the manufacturing process or conditions 
Unit cost (HK$) Annual cost per patient (HK$)
Rituximab 14,496 57,984-115,968
Golimumab 7,000 84,000
Adalimumab 4,830 125,580
Infliximab 4,800 76,800
Table 1. Costs of monoclonal antibodies used to treat rheumatoid 
arthritis in Hong Kong in January 2011.
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may significantly affect immunogenicity, potentially 
changing their efficacy and safety profile, and making 
exact replication a virtual impossibility.
While the structural and therapeutic quality of small-
molecule drugs can be replicated in a consistent 
manner by manufacturers of generic small-molecule 
drugs, biosimilars cannot be considered identical 
generic versions of the reference products as 
their intrinsic complexities, unique cell lines and 
manufacturing processes mean that there will always 
be small variations from the original reference 
agent. The regulatory approval requirements for 
biosimilars also differ from that for generic small 
molecules. Recognising the importance of regulating 
the comparability of biosimilars with the approved 
reference agents, the EMA was the first to establish a 
regulatory framework for the approval of biosimilars in 
the European Union (EU). The first general guidelines 
on biosimilars were published in 20051 followed by 
approval of its first biosimilar in 2006. In the USA, the 
FDA established a regulatory framework for biosimilars 
in 2010 and issued draft guidance on the framework in 
2012.2-5 
To date, the approved agents include somatotropin, 
erythropoietin, and filgrastim biosimilars (Table 2). In 
June 2013, the EMA recommended granting marketing 
authorisations for the first two monoclonal antibody 
biosimilars, Remsima (Celltrion) and Inflectra (Hospira), 
which contain the same known active substance, 
infliximab.6 This marks the first time that the biosimilar 
concept has been successfully applied to molecules as 
complex as monoclonal antibodies. These drugs are 
now awaiting final marketing authorisation decision 
from the European Commission. 
Both the EMA and US FDA require biosimilars to 
have proven comparable levels of quality, efficacy, 
and safety with the reference product.1,2 Fundamental 
features that must be retained in biosimilars include 
the same primary amino acid sequence, potency, 
and route of administration. Higher-order structures, 
post-translational modifications, and other potential 
variants must be as similar as possible with the 
reference product, with adequate analyses performed 
to demonstrate that any differences do not impact upon 
clinical efficacy, safety, or immunogenicity. The specific 
biosimilar given to a patient should also be identifiable 
for pharmacovigilance monitoring. Similarly, the World 
Health Organization (WHO) guidelines specified that 
licensing of biosimilars requires data from clinical trials, 
evaluation of immunogenicity and pharmacovigilance.7
There are many potential differences between 
biosimilars and the reference products such as the 
formulation, post-translational modifications, impurity, 
and potency that could lead to a major difference in the 
product functions. Thus, it is important for regulatory 
authorities to provide a rigorous and balanced approach 
to the approval process. For example, the EMA rejected 
the marketing authorisation of a biosimilar, interferon 
alfa-2a (Alpheon; BioPartners GmbH) in 2006.8 The 
reasons for the rejection included quality and clinical 
differences between the biosimilar and the reference 
product, inadequate data on the stability of the active 
substance, inadequate validation of the process for 
the finished process, and insufficient validation of 
immunogenicity testing.8 Outside the EU and US, the 
regulatory framework for biosimilars varies widely, 
and it is ultimately up to local regulatory authorities 
to decide on the standard and procedures for approval. 
Some so-called ‘biosimilars’ are available in countries 
such as India and over the Internet, which apparently 
meet local regulatory requirements.9 However, as 
these agents do not have proven comparability with 
the original products under the stringent regulatory 
processes issued by the EMA or US FDA, they should 
not be considered biosimilars, but rather, as ‘intended 
copies’ or ‘non-innovator biologics’.10 
DEMONSTRATING BIOSIMILARITY: 
THE APPROVAL PROCESS AND 
OTHER CONSIDERATIONS
The regulatory processes and clinical and non-clinical 
Reference 
product 
Year of 
approval
Brand name (manufacturer) of 
biosimilar
Somatropin 2006 Omnitrope® (Sandoz)
2006 Valtropin® (BioPartners)
Epoetin alfa 2007 Binocrit® (Sandoz)
2007 Epoetin alfa HEXAL® (Hexal)
2007 Abseamed® (Medice Arzneimittel Pütter)
2007 Retacrit® (Hospira)
2007 Silapo® (Stada)
Filgrastim 2008 Ratiograstim® (Ratiopharm)
2008 Filgrastim Ratiopharm® (Ratiopharm)
2008 TevaGrastim® (Teva)
2008 Biograstim® (CT Arzneimittel)
2008 Zarzio® (Sandoz)
2009 Filgrastim HEXAL® (Hexal)
2010 Nivestim® (Hospira)
Table 2. Biosimilars approved in Europe.
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studies required to demonstrate biosimilarity differ 
significantly from requirements for generic drug 
approval, where only bioavailability and bioequivalence 
must be shown. Extensive, non-clinical physiochemical 
and biological characterisation is required to address 
structural, functional, and immunogenicity concerns 
prior to efficacy and safety trials. Both the EMA and 
FDA require clinical data from randomised controlled 
trials to establish equivalent efficacy and safety to 
the reference agent. Furthermore, a suitable primary 
endpoint should be selected to detect differences.2,11,12 
For assessment of rare adverse events and long-term 
efficacy and safety, post-marketing pharmacovigilance 
and risk management plans are required by regulatory 
authorities. Adverse event reports should contain 
as much information as possible, particularly for 
documenting events occurring as a result of switching 
between reference and biosimilar agents. 
Extrapolation of clinical similarity shown in one 
indication to other indications of the reference product 
is allowed by the EMA and FDA, particularly when 
the mechanism of action is the same, and provided 
extrapolation is founded on scientific justification and 
the overall evidence of comparability.4,12 However, 
extrapolation is complex, especially when the drug, such 
as a monoclonal antibody, has different mechanisms 
of action, some of which are not fully understood. For 
example, rituximab can exert its effect through multiple 
mechanisms, including antibody-dependent cellular 
cytotoxicity, complement-dependent cytotoxicity, and 
apoptosis and inhibition of proliferation; moreover, 
the net contribution of each mechanism in vivo is 
unknown.13 In these circumstances, the EMA and FDA 
will consider extrapolation on a case-by-case basis, 
based on totality of evidence.4,12 Potential safety issues 
in different subpopulations should also be addressed.
The ability to differentiate between reference and 
biosimilar agents is also important, hence the use of a 
unique product name for each biosimilar is preferred 
over the generic name to facilitate accurate prescribing 
and tracking. Interchangeability of the biosimilar 
and reference product is controversial because of 
unavoidable differences in immunogenicity that could 
affect hypersensitivity reactions, pharmacokinetics, 
and efficacy. There should be no automatic substitution 
of biosimilar and the reference agent by pharmacists 
without prior consent of the treating physician. For 
safe prescription of biosimilars in clinical practice, it 
is important that biosimilars are prescribed by product 
names, not interchangeable with reference agents, and 
monitored by a robust pharmacovigilance and risk 
management system. 
Because of the manufacturing complexity, stringent 
quality control, longer approval process, and the 
necessity for outcome trials, the magnitude of cost 
saving in producing biosimilars may not be as robust as 
with producing generics. Previous experience suggested 
cost savings of 15 to 30% compared with the reference 
biologic, which is substantially less than the 80 to 
90% cost savings for generic drugs.14,15 In the future, 
expansion of the availability of biosimilars to include 
biosimilar monoclonal antibodies and other agents 
will likely provide new opportunities for cost saving, 
allowing greater patient access to more affordable 
biologic therapy while maintaining high-quality 
standards.
CONCLUSION
The manufacturing of large, complex biologics and 
biosimilars has to be highly controlled, as even minor 
modifications may alter biological function and / or 
immunogenicity, potentially changing the efficacy and 
safety profile. Thus, stringent regulatory processes 
are paramount to ensure that biosimilars have high 
standards of comparability with the reference agents 
at all levels. The currently approved biosimilars have 
provided high-quality and safe therapeutic choices 
to patients, and the hope for the future is to improve 
patient access to a wider range of biologic therapies at 
affordable prices. Once available, physicians should be 
vigilant in the use of biosimilars by prescribing with 
product names, avoiding automatic substitution, and 
closely monitoring patients to ensure long-term safety 
and efficacy of biosimilars. 
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